Danaher’s Integrated DNA Technologies (IDT) announced a collaboration with Profluent Bio to use Profluent’s ProGen3 foundation model for AI‑driven enzyme design, combining IDT’s enzymology and scale‑up capabilities with Profluent’s protein design models. The partnership aims to accelerate enzyme discovery across applications from epigenetics to cancer research. Separately, Genomics unveiled Mystra, an AI‑enabled human genetics platform intended to speed drug target discovery and clinical validation by integrating harmonized GWAS datasets, advanced algorithms and machine‑learning tools. Mystra positions genetics‑backed target selection as a scalable service for biopharma R&D. Both announcements illustrate growing industry investment in foundation models and AI workflows to compress discovery timelines and de‑risk early target selection.